AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well selumetinib works in treating patients with multiple
myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop
the growth of cancer cells by blocking this protein.